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Relapse is the overwhelming cause of treatment failure after autologous transplantation for multiple mye-
loma (MM). For patients with a syngeneic donor, twin transplants provide a healthy graft that is free of my-
eloma. The relative impact of the graft on posttransplant relapse can be estimated by comparing risk of
relapse after hematopoietic cell transplantation from genetically identical twins versus autotransplants be-
cause confounding differences in minor or major histocompatibility antigens are absent in the syngeneic
transplant setting. Outcomes of 43 subjects who received twin transplants for MM were compared to
170 matched autotransplant recipients reported to the Center for International Blood and Marrow Trans-
plant Research (CIBMTR). Multivariate analysis was performed by fitting a Cox model stratified on matched
pairs. The matched transplant patients studied were similar with respect to subject-, disease-, and transplant-
related characteristics. Cumulative incidence of relapse/progression was significantly lower, and progression-
free survival (PFS) was significantly higher following twin transplants. In multivariate analysis, the probability
of relapse/progression was lower in twins (relative risk [RR]5 0.49, 95% confidence interval [CI] 0.28-0.86,
P5 .011). Twin transplants have a significantly lower relapse risk than autotransplants in MM, suggesting that
graft composition may impact outcomes following high-dose chemotherapy.
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Autologous hematopoietic cell transplants (HCT)
are a common therapy with multiple myeloma (MM)
[1,2]. However, relapse/progression is common: actu-
arial posttransplant relapse/progression rates at 5 years
exceed 90% in most series. Posttransplant relapse can118occur because of persisting myeloma cells in the recip-
ient, myeloma cells contaminating the autograft, or
both. Myeloma cells are commonly detected in autolo-
gous grafts [3-9]; but the extent to which this contrib-
utes to posttransplant relapse is unclear. Studies
correlating the degree of myeloma contamination
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posttransplant relapse by decreasing myeloma cells in
the graft have also been unsuccessful [11-13]. Compar-
ison of posttransplant relapse risk after syngeneic ver-
sus autlogous transplants [14,15] provide a basis for
estimating the relative contribution of the graft on
posttransplant relapse after autotransplants.
We analyzed outcomes of all evaluable recipients of
genetically identical twin transplants for MM reported to
the Center for International Blood and Marrow Trans-
plant Research (CIBMTR) between 1988 and 2003
and compared these to outcomes in a similar population
receiving autologous HCT during the same period.
SUBJECTS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP) that comprises a voluntary working group of
.450 transplant centers worldwide that contribute de-
tailed data on consecutive allogeneic and autologous
transplants to a Statistical Center at the Department
of Medicine of the Medical College of Wisconsin in
Milwaukee or the NMDP Coordinating Center in
Minneapolis. Participating centers are required to re-
port all consecutive transplants; compliance is moni-
tored by on-site audits. Subjects are followed
longitudinally, with yearly follow-up. Computerized
checks for errors, physicians’ review of submitted
data and on-site audits of participating centers ensure
data quality. Observational studies conducted by the
CIBMTR are done with a waiver of informed consent
and in compliance with HIPAA regulations as deter-
mined by the institutional review board and the Pri-
vacy Officer of the Medical College of Wisconsin.
The CIBMTR collects data at 2 levels: registration
and research. Registration data include disease type,
age, sex, pretransplant disease stage and chemother-
apy-responsiveness, date of diagnosis, graft type
(bone marrow- and/or blood-derived stem cells),
high-dose conditioning regimen, posttransplant dis-
ease progression and survival, development of a new
malignancy, and cause of death. Requests for data on
progression or death for registered patients are at 6-
month intervals. All CIBMTR teams contribute regis-
tration data. Research data are collected on a subset of
registered patients selected using a weighted random-
ization scheme and include detailed disease, and pre-
and posttransplant clinical information.
Subjects
Between 1988 and 2003, 80 recipients of geneti-
cally identical twin transplants for MM were reportedto the CIBMTR. Comprehensive subject-, disease-,
and transplant-related characteristics were available
for 47 patients. Characteristics and survival of twin
transplant recipients with or without comprehensive
data were similar: survival at 5 years, 58% (95% confi-
dence interval [CI], 42%-73%) versus 67% (32%-
94%), pointwise P 5 .64, log-rank P-value 5 .15.
Subjects receiving tandem transplants (defined as
a planned second transplant or a second transplant
within 6 months of the first without myeloma relapse
or progression in between) were excluded from analy-
sis as were grafts using CD341 selection. The remain-
ing 43 twin transplant recipients were matched to
subjects receiving autologous transplants. There
were 1801 recipients of autologous transplants for
MM available for matching. To adjust for potential
imbalance of risk factors between the cohorts, each
twin transplant recipient was matched with up to 4
autologous transplant recipients as described shortly
(Statistical Analysis section). The final study cohort
consists of 43 twin transplant and 170 autologous
transplant recipients. Eligible cases and controls
came from 82 reporting centers from 20 countries.
Median follow-up of survivors was 88 months for twins
versus 85 months for autotransplant recipients.
Endpoints
The primary endpoint was relapse/progression
and secondary endpoints, treatment-related mortality
(TRM), progression-free survival (PFS), and survival.
Myeloma relapse or progression was defined as 25%
increase either in measurable lesions, bone marrow
plasmacytosis, or M-protein level. TRM was defined
as death from any cause within 28 days posttransplant
or death of any cause thereafter without evidence of re-
lapse or progression. Treatment failure (inverse of
PFS) was defined as the time from transplant to relapse
or death from any cause. For analyses of survival, fail-
ure was death from any cause; survivors were censored
at date of last contact.
Statistical Analyses
A propensity score indicating the predicted proba-
bility of receiving a specific treatment (twin versus
autologous transplant) was calculated conditional on
the following key covariates using logistic regression
modeling. The key risk factors used in fitting the logis-
tic-regression model were age, Durie-Salmon stage at
diagnosis, sensitivity to chemotherapy prior to trans-
plant, time from diagnosis to transplant, and year of
transplant. The numeric propensity scores for recipi-
ents of twin transplants ranged from 0.004 to 0.286.
Twin recipients (cases) were then matched in random
order to autotransplant (control) recipients with simi-
lar propensity scores with the goal of obtaining up to 4
matched controls for each case. Matching involved the
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Syngeneic Autologous
Variable n eval n (%) n eval n (%) P-Value
Patient related:
Number of patients* 43 170
Number of centers 36 54
Age, median (range), years 43 53 (38-69) 170 52 (33-69) .57
Male sex 43 19 (44) 170 98 (58) .12
Karnofsky score pretransplant 43 159 .59
<80 5 (12) 21 (13)
80 8 (18) 34 (21)
90-100 30 (70) 104 (66)
Disease related:
Durie-Salmon stage at diagnosis 43 170 .21
I 6 (14) 14 (8)
II 15 (35) 65 (38)
III 22 (51) 91 (54)
ISS at diagnosis 19 89 .08
I 3 (16) 31 (35)
II 10 (53) 41 (46)
III 6 (31) 17 (19)
Immunochemical subtype of myeloma 43 170 .004
IgG 17 (40) 96 (56)
IgA 8 (19) 34 (20)
Light chain 7 (16) 23 (14)
Nonsecretory 2 (4) 12 (7)
Secretory—others/unknown 9 (21) 5 (3)
Creatinine at diagnosis >2 mg/dL 32 6 (19) 125 21 (17) .69
Radiation prior to transplant 43 9 (21) 170 56 (33) .13
Number of lines of chemotherapy prior to transplant 43 166 .19
1 18 (42) 85 (51)
2 13 (30) 54 (33)
>2 12 (28) 27 (16)
Disease status prior to transplant 42 156 .31
Complete remission 7 (17) 25 (16)
Partial remission 21 (50) 75 (48)
Minimal response/stable 13 (31) 45 (29)
Relapse/progression 1 (2) 11 (7)
Sensitivity to chemotherapy prior to transplant 43 170 .81
Sensitive 26 (60) 105 (62)
Resistant 17 (40) 65 (38)
Creatinine prior to transplant >2 mg/dL 43 4 (9) 162 10 (6) .42
Transplant related:
Time from diagnosis to transplant 43 170 .20
<12 months 26 (60) 112 (66)
$12 months 17 (40) 58 (34)
Conditioning regimen 43 170 .57
Melphalan based—No TBI 17 (40) 84 (49)
Melphalan + TBI ± others 9 (20) 44 (26)
No TBI/No Melphalan
(Bu + Cy and others)† 17 (40) 42 (25)
Graft type 43 170 <.001
BM 19 (44) 14 (8)
PBSC ± BM 24 (56) 156 (92)
Year of transplant 43 170 .51
1988-1992 7 (16) 25 (15)
1993-1997 17 (40) 74 (43)
1998-2003 19 (44) 71 (42)
Planned therapy posttransplant‡ 43 15 (35) 170 78 (46) .22
Median follow-up of survivors, median (range) 88 85
ISS indicates International Staging System; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; LPAM, melphalan; BM, bone marrow; PBSC,
peripheral blood stem cells; EVAL, evaluable.
*Three years of complete follow-up (syngeneic [88%]; autologous [92%]). Four years of complete follow-up (syngeneic [84%]; autologous [91%]).
†The other conditioning regimens for the autologous group were: busulfan + cyclophosphamide (n5 34); other TBI containing regimen (n5 5); Cy +
etoposide + BCNU (n5 1); Cy + etoposide (n5 1), and Cy + etoposide + BCNU + DTIC (n5 1). The other conditioning regimens for the syngeneic
group were: busulfan + cyclophosphamide (n 5 10); other TBI containing regimen (not LPAM) (n 5 7).
‡The type of planned posttransplant therapy for the syngeneic group were: interferon6 others (n5 9); thalidomide6 others (n5 1); biphosphonates
6 others (n5 1) and others, not specified (n5 4). The types of planned posttransplant therapy for the autologous group were: interferon6 others, (n
5 43); IL2/Immunotherapy6 others (n5 3); thalidomide6 others (n5 2); biphosphonates6 others (n5 14); radiation6 others (n5 1) and others,
not specified (n 5 15).
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lected randomly. Any autotransplant recipient with
a difference in propensity score \0.07 5 (0.286-
0.004)/4 was considered a potential matched control;
(2) the matched control with the smallest difference
in propensity score among all potential matched con-
trols was selected; (3) step 1 was repeated among the
remaining cases; (4) steps 1-3 were repeated 4 times.
The final matched cohorts included 43 twin transplant
recipients and 170 autotransplant recipients (42 cases
were found with 4 matches and 1 case with 2 matches).
Baseline subject-, disease-, and transplant-related vari-
ables for the twin and the matched autologous groups
were compared using conditional logistic regression
method to adjust the matching pairs.
Probabilities of PFS and survival were calculated
using the Kaplan-Meier estimator; TRM and re-
lapse/progression were calculated using cumulative in-
cidence estimates. Estimates of standard error for the
survival function were calculated by the Greenwood
formula and 95% CI, using log-transformed intervals.
The log-rank test was used for univariate comparisons.
Multivariate analysis was performed by fitting a Cox
model stratified on matched-pairs. To further adjust
for potential imbalance of risk factors between twin
and autotransplant cohorts, a backward stepwise
model building procedure was used to identify other
risk factors associated with the outcome. The variables
listed in Table 1 except those used in the modeling of
the propensity score were used to build the final
model. Any risk factors found to be significant were ad-
justed in the final Cox model stratified on matched
pairs. All P-values are 2-sided.
RESULTS
Subject Characteristics
Characteristics of subjects receiving twin trans-
plant and controls receiving autotransplants are sum-
marized in Table 1. The groups were well matched
with respect to subject-, disease-, and transplant-re-
lated characteristics. Twin transplant recipients were
more likely to receive bone marrow (BM) grafts versus
peripheral blood stem cell (PBSC) grafts (44% versus
8%; P\ .001). Graft type had no significant impact
on any transplant outcome (data not shown). The dif-
ference in immunochemical subtype between the 2
groups was related to the larger number of patients
in the twin group whose subtype was not specified
and not because of differences in the frequency of
any specified subtype. Sufficient data to determine In-
ternational Staging System (ISS) stage at diagnosis was
available for 19 twin and 89 autotransplant recipients;
the ISS stage was not significantly different between
twin transplant and autotransplant patients (P 5 .08).
Furthermore, outcome parameters were not signifi-cantly different between subjects in whom ISS stage
was or was not determined (data not shown). Cytoge-
netic data were not available for most subjects and was
not considered in multivariate analyses. Two twin
transplant recipients in our study were reported to
have developed graft-versus-host disease (GVHD).
One of them had limited skin involvement that re-
solved before day 100, and the other had liver function
abnormalities that persisted beyond day 100 and then
resolved.
Univariate Analysis
Cumulative incidence of relapse/progression was
significantly lower in twin transplant recipients than
autotransplant recipients at 1 year (10% [95% CI,
3%-20%] versus 26% [95% CI, 19%-33%], P 5
.004); 3 years (40% [95% CI, 25%-55%] versus 59%
[95% CI, 51%-66%], P 5 .026), and 5 years (43%
[95% CI, 28%-59%] versus 71% [95% CI, 64%-
78%], P 5 .002) (Figure 1). Cumulative probability
of TRM at 1, 3, and 5 years for twin transplant recip-
ients was 14% [95% CI, 6%-26%], 14% [95% CI,
6%-26%], and 14% [95% CI, 6%-26%] compared
to 7% [95% CI, 4%-12%], 9% [95% CI, 5%-13%],
and 9% [95% CI, 5%-13%]) for autotransplant recip-
ients (P5NS for all time points). Long-term PFS was
better in twin recipients by log-rank comparison (P 5
.023) and by point-wise comparison at 5 years (42%
[95% CI, 27%-58%] versus 20% [95% CI, 14%-
27%], P 5 .011) (Figure 2); there was no significant
difference at 1 and at 3 years. Survival was also signif-
icantly better for twin versus autotransplant recipients
by point-wise comparison at 5 years (60% [95% CI,
44%-75%] versus 40% [32%-48%], P 5 .028) but
not at 1 and 3 years (Figure 3).
Multivariate Analysis
Results of the multivariate analysis using Cox pro-
portional hazards regression stratified on matched
pairs to analyze outcomes of interest are shown in Ta-
ble 2. Twin recipients were significantly less likely to
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Figure 1. Cumulative incidence of relapse after HSCT for MM, by type
of transplant.
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0.28-0.86; P 5 .011). Risk of treatment failure (RR 5
0.64; 0.40-1.05; P 5 .08), TRM (RR 5 2.31; 0.82-
6.51; P 5 .10) and survival (RR 5 0.68; 0.40-1.16,
P 5 .10) were not significantly different.
Long-Term Survival
Five of 213 subjects were alive after 10 years (Table
3). One twin and 1 autotransplant recipient are re-
lapse-free survivors at 10.7 and 12.6 years, respec-
tively. Another twin transplant recipient relapsed 2.9
years after the first transplant but is in remission at
10.6 years after a second transplant from the same do-
nor. No twin transplant recipient surviving .10 years
posttransplant was reported to have developed
GVHD.
DISCUSSION
Our study shows that twin transplant recipients
have a significantly lower risk of myeloma relapse/pro-
gression than autotransplant recipients. A smaller re-
port from the European Group for Blood and
Marrow Transplantation (EBMT) [15] has also sug-
gested that twin transplant recipients have a signifi-
cantly lower risk of myeloma relapse/progression
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Figure 2. Probability of PFS after HSCT for MM, by type of transplant.
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type of transplant.compared to autotransplant recipients. Our study con-
firms that observation using a larger sample size of
twin transplants (43 patients versus 25) longer fol-
low-up (median follow-up 88 months versus 29
months) and stringent matching based upon Propen-
sity Score. Our results are also consistent with a similar
study by the CIBMTR in persons with low-grade non-
Hodgkin lymphoma (NHL) [16] showing significantly
lower relapse risk in twin versus autotransplant recip-
ients in that disease.
Several prior studies have suggested that allogeneic
transplants are associated with a lower relapse risk than
autotransplants in myeloma [15-18]. Our data suggest
that a myeloma free graft can significantly alter post-
transplant relapse risk even in the absence of disparity
in histocompatibility genes seen with allogeneic trans-
plants. There are, however, some cautions. For exam-
ple, our analysis was retrospective and cytogenetic
data were not available on all patients. Although an
imbalance in cytogenetic risk groups may explain
the difference we found, this is unlikely given the com-
parability of the twin transplant and autotransplant
groups with respect to other patient and disease-related
factors.
Several factors may explain the lower relapse risk
seen in twin transplant recipients. In contrast to auto-
transplants, grafts from twins are free of contamination
Table 2. Relative Risks of Relapse, Treatment-Related
Mortality, Treatment Failure, and Mortality with Autologous
versus Syngeneic Transplants in Multivariate Analysis*
Outcome Event Relative Risk (95% CI) P-Value†
Treatment-related mortality
Autologous 1.00‡
Syngeneic 2.31 (0.82 - 6.51) .10
Relapse/progression
Autologous 1.00‡
Syngeneic 0.49 (0.28-0.86) .011
Treatment failure
Autologous 1.00‡
Syngeneic 0.64 (0.40-1.05) .08
Mortality
Autologous 1.00‡
Syngeneic 0.68 (0.40-1.16) .15
CI indicates confidence interval.
*Multivariate results are based on fitting a Cox model stratified on
matched pairs.
†Score test.
‡Reference group.
Table 3. Long-Term Survivors following Syngeneic or
Autologous Transplantation
Transplant
Time to
Relapse, Years
Status at Last
Contact Date
Time from tx to Last
Contact Date, Years
Autologous no CR 12.6
Autologous 7.4 PR 12.1
Autologous 5.3 NR/SD 10.14
Syngeneic 2.9 CR 13.45
Syngeneic no CR 10.7
tx indicates transplant.
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grafts with myeloma cells is common [3-6,8,9,12,17].
Some data correlate extent of graft contamination to
the likelihood of relapse [8]. Interpretations of these
data are complex. One conclusion from these is that re-
moving myeloma cells from the graft may decrease
posttransplant relapse-risk. However, a recent gene-
marking study failed to demonstrate evidence of re-
lapse from marked cells within the autograft although
the sample size was rather small [19]. Furthermore,
randomized [13], and nonrandomized [10,12] studies
of attempted purging of myeloma from the graft
show no clear benefit. Whether this represents insuffi-
cient purging or other factors that confound the effect
of graft manipulation is unclear. For example purging
of the graft may also eliminate some immune effector
cells that inhibit relapse posttransplant. Also, immune
cells in the normal twin graft are likely to be healthy,
and could have a stronger antimyeloma effect than re-
cipient immune cells (in an autograft), which may be
exposed to prior therapy. However, there are few
data suggesting an effective immune-mediated anti-
myeloma effect except in the setting of HLA-disparity
(which does not apply here). Also, although GVHD
has been reported in twin transplant recipients
[15,20] it is difficult or impossible to diagnose accu-
rately, as is the case in our study. In allogeneic trans-
plants, graft-versus-myeloma effects are strongly
correlated with moderate to severe GVHD [21,22].
Thus, it is unlikely that the mild GVHD reported in
only 2 twin transplant recipients in this study is the
predominant explanation for the lower relapse risk.
Similarly, although the twin transplant patients were
significantly more likely to receive BM versus PBSC
grafts, no significant effect of graft type (marrow versus
peripheral blood) on outcome was detectable on mul-
tivariate analysis. Furthermore, there are no data
within the literature to suggest that in MM, BM grafts
are superior to PBSC grafts. Our study confirms previ-
ous reports of long-term myeloma-free survival after
high-dose therapy and twin transplants in some pa-
tients [14,15].
The observed long-term TRM rate was higher
among the twin transplants than the autotransplants
(14% versus 7%, RR 2.31). Although this difference
was not statistically significant because of the sample
size, it may been related to the higher frequency of
BM versus PBSC grafts in the twins, and may have re-
duced the benefit of the reduced relapse rate seen in the
twins upon PFS and OS.
In summary, this largest reported study of synge-
neic transplantation in myeloma confirms that twin
transplants have a lower relapse risk than comparable
autotransplants. The results seen in the twins may be
the best that could potentially be achieved following
autografts if all contaminating myeloma cells could
be removed from the graft. Although the exact mech-anism behind the advantage demonstrated for twin
transplants cannot be defined, lack of graft contamina-
tion with myeloma, subclinical graft-versus-tumor ef-
fects that are independent of HLA disparity, and
a graft unexposed to prior therapy may all have con-
tributed. Attempts to improve the outcome of autolo-
gous transplants in myeloma may need to address these
mechanisms. Furthermore, reduction in the myeloma
burden in the graft may be of greater significance if
the total body burden of myeloma is more substantially
reduced pretransplant, as it may now be achieved using
novel induction therapies.
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